Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.52 USD
Change Today -0.29 / -2.96%
Volume 50.0K
GNMK On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 3:33 PM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

genmark diagnostics inc (GNMK) Snapshot

Open
$9.87
Previous Close
$9.81
Day High
$9.90
Day Low
$9.51
52 Week High
01/5/15 - $14.40
52 Week Low
08/7/15 - $7.57
Market Cap
403.5M
Average Volume 10 Days
247.4K
EPS TTM
$-0.97
Shares Outstanding
42.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENMARK DIAGNOSTICS INC (GNMK)

Related News

No related news articles were found.

genmark diagnostics inc (GNMK) Related Businessweek News

No Related Businessweek News Found

genmark diagnostics inc (GNMK) Details

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. The company’s products include XT-8 system, an automated molecular diagnostic system that enables reference laboratories and hospitals to perform molecular diagnostic tests. The company offers eight diagnostic tests for use with its XT-8 system that includes Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test, Respiratory Viral Panel, hepatitis C virus, genotyping tests, a 3A4/3A5 genotyping test, and a 2C19 genotyping test. It also provides ePlex system, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using the ePlex system to place the patient sample into the test cartridge and obtain results without any additional steps. Genmark Diagnostics, Inc. is headquartered in Carlsbad, California.

195 Employees
Last Reported Date: 02/24/15

genmark diagnostics inc (GNMK) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $450.0K
Chief Financial Officer
Total Annual Compensation: $189.5K
Senior Vice President of North American Comme...
Total Annual Compensation: $245.4K
Senior Vice President of International
Total Annual Compensation: $154.8K
Senior Vice President of Human Resources
Total Annual Compensation: $250.0K
Compensation as of Fiscal Year 2014.

genmark diagnostics inc (GNMK) Key Developments

GenMark Diagnostics, Inc. Announces Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Reaffirms Earnings Guidance for the Year 2015

GenMark Diagnostics, Inc. announced consolidated unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported total revenue of $7,646,000 against $6,555,000 a year ago. Loss from operations was $11,930,000 against $11,265,000 a year ago. Loss before provision for income taxes was $12,153,000 against $11,191,000 a year ago. Net loss was $12,152,000 against $11,210,000 a year ago. Net loss per basic and diluted share was $0.29 against $0.27 a year ago. The annuity per analyzer in the second quarter was approximately $52,000, and this is typical for the non-flu season. For the six months, the company reported total revenue of $17,753,000 against $14,468,000 a year ago. Loss from operations was $21,957,000 against $20,124,000 a year ago. Loss before provision for income taxes was $21,999,000 against $19,967,000 a year ago. Net loss was $22,021,000 against $19,993,000 a year ago. Net loss per basic and diluted share was $0.53 against $0.49 a year ago. Net cash used in operating activities was $15,858,000 against $13,519,000 a year ago. Payments for intellectual property licenses were $550,000. Purchases of property and equipment were $2,243,000 against $2,626,000 a year ago. For full year 2015, the company continues to expect revenue in the range of $38 million to $40 million. Gross margin expectations for the full year are being increased to 57% to 59%. The company expects to place approximately 25-35 additional xt-8 analyzers in the second half of the year. Fourth quarter average annuity per analyzer is in the mid-$50,000 range.

GenMark Diagnostics, Inc. to Report Q2, 2015 Results on Aug 06, 2015

GenMark Diagnostics, Inc. announced that they will report Q2, 2015 results at 5:00 PM, Eastern Standard Time on Aug 06, 2015

GenMark Diagnostics, Inc., Q2 2015 Earnings Call, Aug 06, 2015

GenMark Diagnostics, Inc., Q2 2015 Earnings Call, Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNMK:US $9.52 USD -0.29

GNMK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Great Basin Scientific Inc $0.17 USD -0.0395
Nanosphere Inc $2.68 USD 0.00
Quidel Corp $20.77 USD -0.68
Seegene Inc 45,200 KRW +400.00
T2 Biosystems Inc $11.30 USD +0.28
View Industry Companies
 

Industry Analysis

GNMK

Industry Average

Valuation GNMK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.0x
Price/Book 0.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENMARK DIAGNOSTICS INC, please visit www.genmarkdx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.